Skip to content
IMRXImmuneering Corp

Earnings

When Immuneering Corp reports, what it reported each quarter, and how the stock took the results.

27 quarters. Mar 31, 2020 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 5, before the open

Fri, Mar 5, 2027in 108 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 1 – 23

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q4 2023 −100.0%, Q3 2023 −100.0%, Q2 2023 −100.0%, Q1 2023 −100.0%
Net income
-$11.58M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q4 2023 · derived$0.00−100.0% vs Q4 2022

Latest results

  1. Q3 2026Oct 29, 2026, after the closeThe release7.0%by the close of Oct 30
    Revenue
    —
    —
    Net income
    -$24.19M
    N/M
    EPS
    -$0.37
    N/M
    On October 29, 2026, Immuneering Corporation (the “Company”) announced its financial results for the quarter ended September 30, 2026 and provided operational updates.
  2. Q2 2026Aug 5, 2026, before the openThe release0.5%by the close of Aug 5
    Revenue
    —
    —
    Net income
    -$17.27M
    N/M
    EPS
    -$0.27
    N/M
  3. Q1 2026May 15, 2026, before the openThe release+0.4%by the close of May 15
    Revenue
    —
    —
    Net income
    -$13.46M
    N/M
    EPS
    -$0.21
    N/M
  4. Q4 2025Mar 6, 2026, before the openThe release+6.8%by the close of Mar 6
    Revenue
    —
    —
    Net income
    -$11.58M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Oct 29, 2026 · after-hoursOct 29, 202629 d10-Q——-$0.377.0%
Q2 2026Jun 30, 2026Aug 5, 2026 · pre-marketAug 5, 202636 d10-Q——-$0.270.5%
Q1 2026Mar 31, 2026May 15, 2026 · pre-marketMay 15, 202645 d10-Q——-$0.21+0.4%
FY 2025
Q4 2025derivedDec 31, 2025Mar 6, 2026 · pre-marketMar 6, 202665 d10-K———+6.8%
Q3 2025Sep 30, 2025Nov 12, 2025 · after-hoursNov 12, 202543 d10-Q——-$0.382.6%
Q2 2025Jun 30, 2025Aug 13, 2025 · after-hoursAug 13, 202544 d10-Q——-$0.406.3%
Q1 2025Mar 31, 2025May 5, 2025 · after-hoursMay 5, 202535 d10-Q——-$0.422.4%
FY 2024
Q4 2024derivedDec 31, 2024Mar 20, 2025 · after-hoursMar 20, 202579 d10-K———+9.8%
Q3 2024Sep 30, 2024Nov 13, 2024 · after-hoursNov 13, 202444 d10-Q——-$0.49+13.5%
Q2 2024Jun 30, 2024Aug 6, 2024 · after-hoursAug 6, 202437 d10-Q——-$0.478.1%
Q1 2024Mar 31, 2024May 7, 2024 · after-hoursMay 7, 202437 d10-Q——-$0.495.5%
Earlier years, FY 2020 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QOct 29, 2026000097
10-QAug 5, 2026000091
10-QMay 15, 2026000057
10-KMar 6, 2026000042
10-QNov 12, 2025000135
10-QAug 13, 2025000104
10-QMay 5, 2025000061
10-KMar 20, 2025000042
10-QNov 13, 2024000080
10-QAug 6, 2024000066

Provenance

ProvenanceData status and checks

Immuneering Corp · CIK 1790340 · Engraved from SEC EDGAR